This website has been developed by Besins Healthcare (UK) Ltd.
This website has separate sections for healthcare professionals (containing promotional information), and patients who have been prescribed Testogel® (testosterone) 16.2 mg/g gel, within the UK.
Please confirm that:
Kim, aged 38
Patient profile is fictional and for illustrative purposes only.
Testosterone therapy can reduce the risk of long-term adverse metabolic and cardiovascular impact in patients with testosterone deficiency (TD).1-3†
In a 6-month double-blind randomised placebo-controlled trial of young male cancer survivors (TRYMS study), testosterone therapy was associated with significant improvement in body composition in testicular cancer survivors vs. placebo at 26 weeks.3
Boxes represent the interquartile range, circles indicate the mean, lines inside the box indicate the median, whiskers represent the range excluding outliers, and asterisks indicate outliers.
Adapted from Walsh JS, et al. 2019.
The active treatment in the above study was testosterone 2% gel (Kyowa Kirin).
†The studies include data on patients receiving a range of testosterone therapies including gels.
Obesity, diabetes, metabolic syndrome and cardiovascular disease are closely related conditions that all have negative long-term health effects.4-6
If you would like to discover more about how Testogel® 16.2 mg/g gel can help your patients, please complete a request form.
TES/2020/009. April 2021.
Adverse event reporting
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: firstname.lastname@example.org